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The role of cGMP and cGMP-dependent protein kinase
type I (cGKI) in the phenotypic modulation and growth
of vascular smooth muscle cells (VSMCs) is not well
understood. The general view, which is mainly based on
the in vitro analysis of subcultured (repeatedly passaged)
cells, is that activation of the cGMP/cGKI pathway inhibits
the proliferation of VSMCs. In contrast, recent in vivo
studies with transgenic mice indicated that cGMP/cGKI
signaling in VSMCs promotes vasculo-proliferative proc-
esses. Here, we have studied the effects of various "cGK
agonists" (8-Br-cGMP, 8-pCPT-cGMP, 8-Br-PET-cGMP)
and "cGK inhibitors" (Rp-8-pCPT-cGMPs, Rp-8-Br-PET-
cGMPs, DT-2) on the growth of primary aortic VSMCs
from control and cGKI-deficient mice. All tested agonists
stimulated the growth of primary VSMCs via activation of
cGKI, whereas the tested "cGK inhibitors" failed to inhibit
cGKI activity and cell growth. 8-Br-cAMP, an activator of
the cAMP-dependent protein kinase (cAK), inhibited the
growth of both wild-type and cGKI-deficient cells. These
results suggest that (i) activation of the cGMP/cGKI path-
way stimulates the growth of primary VSMCs, (ii) "cGKI
inhibitors" should be used with caution in intact VSMCs,
and (iii) cAMP inhibits VSMC growth by an cGKI-inde-
pendent mechanism. Interestingly, the growth of various
subcultured VSMC lines (obtained from rat and human
media and intima) was barely affected by cGMP, but
strongly inhibited by cAMP. Taken together, these results
indicate that the effects of cGMP on VSMC growth differ
between primary and subcultured cells. In primary
VSMCs, cGMP stimulates growth via activation of cGKI. In
contrast, subcultured cells appear to be refractory to
growth stimulation by cGMP and cGKI, perhaps because
repeated passaging results in dysregulation of the cGMP/
cGKI pathway or in more general alterations of prolifera-
tive responses. The reported anti-proliferative effect of
cGMP analogs on subcultured VSMCs might be caused by
cross-activation of the cAMP/cAK pathway.
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